Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. - Wikidata - wikimedia - TriplyDB

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

http://www.wikidata.org/entity/Q37653023

about

A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: focusing on mitochondria Pathologic and therapeutic implications for the cell biology of parkin Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics Reactive nitrogen species in cellular signaling The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders Impact of Antioxidants on Cardiolipin Oxidation in Liposomes: Why Mitochondrial Cardiolipin Serves as an Apoptotic Signal?Identification of licopyranocoumarin and glycyrurol from herbal medicines as neuroprotective compounds for Parkinson's disease In vivo screening reveals interactions between Drosophila Manf and genes involved in the mitochondria and the ubiquinone synthesis pathway.Arctigenin enhances swimming endurance of sedentary rats partially by regulation of antioxidant pathways.Mitochondria-targeting particles.The role of mitochondrial DNA mutation on neurodegenerative diseases.Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.Exosomes as drug delivery vehicles for Parkinson's disease therapy Solid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.Mitochondria-Targeting Magnetic Composite Nanoparticles for Enhanced Phototherapy of Cancer.Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model.Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells Molecular cloning, epigenetic regulation, and functional characterization of Prkd1 gene promoter in dopaminergic cell culture models of Parkinson's disease.Role of proteolytic activation of protein kinase Cδ in the pathogenesis of prion disease.Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease.Synthesis of hydroxycinnamic acid derivatives as mitochondria-targeted antioxidants and cytotoxic agents.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Increased risk of Parkinson disease with diabetes mellitus in a population-based study.Redox control of enzymatic functions: The electronics of life's circuitry.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.The ongoing pursuit of neuroprotective therapies in Parkinson disease.New insights on the mitochondrial proteome plasticity in Parkinson's disease.Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity: IMPLICATIONS FOR PARKINSON DISEASE.The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained.Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.The antioxidant protein Oxr1 influences aspects of mitochondrial morphology Sirtuins as modifiers of Parkinson's disease pathology.Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery.Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases.Mitochondria-targeted nutraceuticals in sports medicine: a new perspective.Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors.Prospects for therapeutic mitochondrial transplantation.Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation.

P2860

Q26781560-2519F216-883B-4ADC-82DC-FE9E5E456E21 Q26991957-DFB24029-36B4-47B3-8F1C-6BC01113560D Q27010567-6CF534CE-E5F1-460C-BFD4-9379B3B54264 Q28069321-4F8D270F-AEE0-4A87-AB37-BB8C9E7AE93B Q28383441-D5750CBB-4889-4A92-84FC-B2EC3E0AC959 Q28395641-C2CFCE68-BA20-4BB8-82E0-F77A8E8F46F3 Q28396467-30191E2E-592E-4BA8-AA3A-E1D2CC9D522F Q28539943-209D67F3-9CC6-4CE4-A1C8-886DB2410A1A Q30854473-43722ACB-8BE9-4E41-81AD-597A3305443F Q34295032-56D8E548-791D-471A-BEAE-3550A3D90336 Q34960940-18E5B1E7-069D-4BAB-B494-F567F8D8F513 Q35152954-1282590F-F751-45ED-8236-E974868436F5 Q35164624-5F3C32F1-5727-4888-9849-FD8DF9FBCD61 Q35602589-27D0E489-0615-455B-B811-9D5E490C1063 Q35794829-F1754C69-4CE2-471E-8649-8B43ED05CF29 Q36070661-08103BF8-B79D-415A-9E60-D47EAD61390D Q36234714-1CB95B16-B16B-4776-AD30-9F48E941F5D9 Q36422034-36B15671-8EE2-4B0E-B530-BBCAE6E24B58 Q36727515-6E74A86E-59BF-454E-9100-94D311B7DF7F Q36821650-DF7207FB-CDBB-4719-A34F-A3AA84812421 Q37184038-29DB0128-8CBC-4892-9638-12F570DB80CF Q37539279-6EB56D81-53C8-42BF-9D8A-CFF79E36CB14 Q37587300-BAD352D9-B8D6-44A4-9166-7F2724B7F725 Q37607467-49457182-45A7-4621-B73B-FFA8C4EF9228 Q37613409-C4246028-0733-4867-BB4D-B1BCC3720356 Q38199448-DD8C218D-EBE4-425F-8CC9-6603ED8012C0 Q38202314-FF7CB421-2782-4592-BD33-6BB802A30156 Q38275171-20A21CFF-54E7-4E44-9538-D97F4A24251E Q38452561-DD523738-0C54-457C-AC9A-492E2DA85113 Q38787990-1A04049D-1CA2-457C-AC6E-EC4EF2427CA1 Q38841508-9F4304E9-0003-4007-A48B-A98F68F96FBC Q38855994-AA99FB16-8805-46E3-93C0-24CAA61285F6 Q38887200-38D381E7-F587-4869-BF74-49D7B295B7D3 Q38893382-19344118-53ED-4654-A991-B1E054D731E0 Q38910964-B7DB12D5-3FA8-446E-BF38-C9E78B262F9D Q38972042-F730A623-3108-46C8-B5C7-6DA426FC5213 Q39010874-EF17B087-EA41-460D-976C-34D2B4CA1B49 Q39205930-C676E8BE-B9FB-432D-81E4-B3FE13204226 Q39323349-B6744E23-14FA-4313-AC8B-1E333FE2858E Q40401995-E0610844-2E66-4A21-8631-DFDFC6E6F90D

P2860

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

http://www.wikidata.org/entity/Q37653023

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@en

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@nl

type

label

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@en

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@nl

prefLabel

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@en

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@nl

P1433

Q37653023-3A8D6980-82D1-48A2-839F-415666C5E74A

P1476

Q37653023-5706FE29-B7C1-457E-97F8-8C8C0C582048

P2093

Q37653023-0C04063F-D610-4CF0-BCA1-56C4EC0666D9

Q37653023-12F398DD-9177-4EC1-9F61-121F9DCC0634

Q37653023-1C5CF0AD-6622-40BF-B6CE-A44D1301148D

Q37653023-27405A2E-4CEC-4823-B95D-C2D64D6C482F

Q37653023-47384734-484E-4B9D-B0DD-3B0608FAE4FB

Q37653023-C082049C-C99A-4468-B13C-D695764597A0

P2860

Q37653023-031286E4-2376-4CFD-84B9-823288EDC482

Q37653023-0312DBDA-9B2E-4F70-A577-8A4F08F3DA6C

Q37653023-03E4A006-BB65-4FCD-B1EB-A5D3D254D694

Q37653023-053F8EB3-445E-4533-B566-11E02009F292

Q37653023-0693E354-8669-4717-AF95-7141E01DBE64

Q37653023-0807316F-5E88-4DC1-9C34-C77E8B19B22C

Q37653023-085F64C4-6F46-4CFE-9310-B22680570068

Q37653023-08B7F481-DDF7-48A4-8A1F-D399B2640318

Q37653023-0A6BB77A-682E-4CCB-93E9-5B9CE63B33C0

Q37653023-0BDFB01E-5913-4031-80A9-3129BB815B0E

P304

Q37653023-93CF3A2B-9237-4064-A411-1CB9F42039D9

P31

Q37653023-DEA3F146-0B4B-408A-9265-1D656F25EE7B

P356

Q37653023-9B106251-FBFA-4498-9C86-1F0EB07661F7

P407

Q37653023-48D3C0FD-81B0-49C0-A878-D79708075FEB

P433

Q37653023-6C1EFB7F-048C-42C2-9465-8C3740183789

P478

Q37653023-F6F0AC19-982D-46DE-851E-FC8F491CA098

P577

Q37653023-2BD644E1-301D-41B7-848D-68FE6D7DCE00

P5875

Q37653023-9662A1C0-19F2-4686-BAE1-4AA9CE587C4C

P698

Q37653023-6A833E03-441D-40AE-9183-E20B6190C483

P921

Q37653023-A45FCBEA-F15C-4C17-BE1C-F19FA1E28515

Q37653023-E58EF467-E992-4B2D-9FB6-168498B170DE

P932

Q37653023-1470C250-9D63-401D-9FB5-85E4A4AD7743

P356

J.BBADIS.2013.09.007

P1433

Biochimica et Biophysica Acta

P1476

Mitochondria-targeted antioxid ...... linical and clinical outcomes.

@en

P2093

Anamitra Ghosh

http://www.w3.org/2001/XMLSchema#string

Anumantha G Kanthasamy

http://www.w3.org/2001/XMLSchema#string

Arthi Kanthasamy

http://www.w3.org/2001/XMLSchema#string

Balaraman Kalyanaraman

http://www.w3.org/2001/XMLSchema#string

Huajun Jin

http://www.w3.org/2001/XMLSchema#string

Vellareddy Anantharam

http://www.w3.org/2001/XMLSchema#string

P2860

The promise of neuroprotective agents in Parkinson's disease

Proteome analysis of human substantia nigra in Parkinson's disease

SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS

Missing pieces in the Parkinson's disease puzzle

Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis

Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis

Free radicals in the physiological control of cell function

Oxidants, oxidative stress and the biology of ageing

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase

P304

1282-1294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBADIS.2013.09.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

1842

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256983504

http://www.w3.org/2001/XMLSchema#string

P698

24060637

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3961561

http://www.w3.org/2001/XMLSchema#string